866-997-4948(US-Canada Toll Free)

Swine Influenza - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : May 2014

Category :

Wine

No. of Pages : 31 Pages

Global Markets Directs, Swine Influenza Pipeline Review, H1 2014, provides an overview of the Swine Influenzas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Swine Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Swine Influenza and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Swine Influenza
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Swine Influenza and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Swine Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Swine Influenza pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Swine Influenza
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Swine Influenza pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Swine Influenza Overview 6
Therapeutics Development 7
Pipeline Products for Swine Influenza - Overview 7
Pipeline Products for Swine Influenza - Comparative Analysis 8
Swine Influenza - Therapeutics under Development by Companies 9
Swine Influenza - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Swine Influenza - Products under Development by Companies 12
Swine Influenza - Companies Involved in Therapeutics Development 13
Novartis AG 13
Aprogen, Inc. 14
Pike Pharma GmbH 15
Swine Influenza - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
H3N2c Vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Influ-nRNA - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AP-302 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GREFLU/CAL - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit Polymerase Subunit Interactions for Influenza - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Swine Influenza - Recent Pipeline Updates 29

Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Table


Number of Products under Development for Swine Influenza, H1 2014 7
Number of Products under Development for Swine Influenza - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Swine Influenza - Pipeline by Novartis AG, H1 2014 13
Swine Influenza - Pipeline by Aprogen, Inc., H1 2014 14
Swine Influenza - Pipeline by Pike Pharma GmbH, H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 18
Number of Products by Stage and Mechanism of Action, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 21
Number of Products by Stage and Molecule Type, H1 2014 23
Swine Influenza Therapeutics - Recent Pipeline Updates, H1 2014 29

List of Chart


Number of Products under Development for Swine Influenza, H1 2014 7
Number of Products under Development for Swine Influenza - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Target, H1 2014 17
Number of Products by Stage and Top 10 Target, H1 2014 18
Number of Products by Top 10 Mechanism of Action, H1 2014 19
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 20
Number of Products by Top 10 Molecule Type, H1 2014 22
Number of Products by Stage and Top 10 Molecule Type, H1 2014 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *